Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Aglaya G, Iyevleva"'
Autor:
Natalia V. Mitiushkina, Alexandr A. Romanko, Elena V. Preobrazhenskaya, Vladislav I. Tiurin, Tatiana I. Ermachenkova, Alexandr S. Martianov, Rimma S. Mulkidjan, Tatiana N. Sokolova, Maksim M. Kholmatov, Ilya V. Bizin, Alexandr O. Ivantsov, Olga S. Yatsuk, Olga A. Zaitseva, Aglaya G. Iyevleva, Ekatherina Sh. Kuligina, Evgeny N. Imyanitov
Publikováno v:
Cancer Medicine, Vol 11, Iss 17, Pp 3226-3237 (2022)
Abstract Background Despite the progress in the development of next‐generation sequencing (NGS), diagnostic PCR assays remain to be utilized in clinical routine due to their simplicity and low cost. Tests for 5′‐/3′‐end mRNA unbalanced expr
Externí odkaz:
https://doaj.org/article/d38a620319e847078e9a0ddad75d9206
Autor:
Tatiana N. Sokolova, Svetlana N. Aleksakhina, Grigoriy A. Yanus, Aleksandr V. Sultanbaev, Konstantin V. Menshikov, Anna N. Lysenko, Ruslan A. Zukov, Alena V. Zyuzyukina, Yulia N. Murunova, Elena I. Rossokha, Sergey Y. Bakharev, Elena A. Basova, Tatiana A. Kasmynina, Irina S. Shumskaya, Yana I. Bakshun, Khedi S. Musaeva, Alfia I. Khasanova, Vadim N. Dmitriev, Marina B. Bolieva, Christina H. Gadzaova, Oleg L. Petrenko, Dmitriy A. Maksimov, Vladimir I. Vladimirov, Viktor E. Goldberg, Nataliya O. Popova, Marianna V. Kibisheva, Zaur M. Khamgokov, Alexey E. Vasilyev, Aglaya G. Iyevleva, Evgeny N. Imyanitov
Publikováno v:
Современная онкология, Vol 23, Iss 1, Pp 61-67 (2021)
Relevance. PIK3CA belongs to the top three most frequently mutated genes in breast cancer (BC), especially in estrogen receptor (ER) positive, HER2 negative BC subtype. With an approval of selective PI3K-alpha inhibitor, alpelisib, this alteration ha
Externí odkaz:
https://doaj.org/article/49ac17b627194a6ea7e6222ff26d5a94
Autor:
Sergey V. Orlov, Aglaya G. Iyevleva, Elena A. Filippova, Alexandra M. Lozhkina, Svetlana V. Odintsova, Tatiana N. Sokolova, Natalia V. Mitiushkina, Vladislav I. Tiurin, Elena V. Preobrazhenskaya, Alexandr A. Romanko, Alexandr S. Martianov, Alexandr O. Ivantsov, Svetlana N. Aleksakhina, Alexandr V. Togo, Evgeny N. Imyanitov
Publikováno v:
Translational Oncology, Vol 14, Iss 8, Pp 101121- (2021)
Background: Lorlatinib is a novel potent ALK inhibitor, with only a few studies reporting the results of its clinical use. Methods: This study describes the outcomes of lorlatinib treatment for 35 non-small cell lung cancer patients with ALK rearrang
Externí odkaz:
https://doaj.org/article/7a54773d24a54c3d9f4951da25379307
Autor:
Kristina V. Orlova, Grigory A. Yanus, Svetlana N. Aleksakhina, Aigul R. Venina, Aglaya G. Iyevleva, Lev V. Demidov, Evgeny N. Imyanitov
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 1, Pp 109-112 (2019)
Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not stu
Externí odkaz:
https://doaj.org/article/cd7fea8bbb3647aab83a322416cf626f
Autor:
Evgeny N Imyanitov, Ekaterina S Kuligina, Anna P Sokolenko, Evgeny N Suspitsin, Grigoriy A Yanus, Aglaya G Iyevleva, Alexandr O Ivantsov, Svetlana N Aleksakhina
Publikováno v:
World Journal of Clinical Oncology. 14:40-68
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b39caeddfe48fc7ae44d77f0393e39f7
https://doi.org/10.5306/wjco.v14.i2.40
https://doi.org/10.5306/wjco.v14.i2.40
Autor:
Aglaya G. Iyevleva, Svetlana N. Aleksakhina, Anna P. Sokolenko, Sofia V. Baskina, Aigul R. Venina, Elena I. Anisimova, Ilya V. Bizin, Alexandr O. Ivantsov, Yana V. Belysheva, Alexandra P. Chernyakova, Alexandr V. Togo, Evgeny N. Imyanitov
Publikováno v:
Breast Cancer Research and Treatment. 192:283-291
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e086ed9674dd019b4a58a45c41a69c91
https://doi.org/10.1007/s10549-022-06517-3
https://doi.org/10.1007/s10549-022-06517-3
Autor:
Anna P. Sokolenko, Fedor V. Moiseyenko, Aglaya G. Iyevleva, Alexandr O. Ivantsov, Georgiy D. Dolmatov, Ksenia V. Shelekhova, Elizaveta V. Gulo, Anastasya X. Topal, Elizaveta V. Artemieva, Nuriniso H. Abduloeva, Nikita A. Rysev, Daria A. Barsova, Natalia V. Levchenko, Nikita M. Volkov, Vitaliy V. Egorenkov, Vladimir M. Moiseyenko, Evgeny N. Imyanitov
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 3; Pages: 1870
Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer cells. It is unclear whether the use of ultrasensitive genetic methods may still detect resid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd67cf2ee7392c706f8da4b994ca5076
Autor:
Artem Kosmin, Vadim Dmitriev, Aglaya G. Iyevleva, Tatiana N. Sokolova, Vladimir Moiseenko, Svetlana N. Aleksakhina, Evgeny N. Imyanitov, Tatiana Solovieva, Mikhail M Kramchaninov, Vladislav Petkau
Publikováno v:
Problems in oncology. 67:646-657
Background. More than half of breast carcinomas express estrogen and progesterone receptors (ER and PR) and remain estrogen-dependent. Endocrine therapy with inhibitors of the estrogen cascade allows long-term and effective control of the disease in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24e0527d52d037f7213fb3efcc10ebff
https://doi.org/10.37469/0507-3758-2021-67-5-646-657
https://doi.org/10.37469/0507-3758-2021-67-5-646-657
Autor:
Aleksandr S. Martianov, Natalia V. Mitiushkina, Anastasia N. Ershova, Darya E. Martynenko, Mikhail G. Bubnov, Priscilla Amankwah, Grigory A. Yanus, Svetlana N. Aleksakhina, Vladislav I. Tiurin, Aigul R. Venina, Aleksandra A. Anuskina, Yuliy A. Gorgul, Anna D. Shestakova, Mikhail A. Maidin, Alexey M. Belyaev, Liliya S. Baboshkina, Aglaya G. Iyevleva, Evgeny N. Imyanitov
Publikováno v:
International Journal of Molecular Sciences
Volume 24
Issue 5
Pages: 4868
Volume 24
Issue 5
Pages: 4868
This study aimed to analyze clinical and regional factors influencing the distribution of actionable genetic alterations in a large consecutive series of colorectal carcinomas (CRCs). KRAS, NRAS and BRAF mutations, HER2 amplification and overexpressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdecc5a970257f7d069339ddef51dfc2
https://doi.org/10.3390/ijms24054868
https://doi.org/10.3390/ijms24054868
Autor:
Aglaya G, Iyevleva, Svetlana N, Aleksakhina, Anna P, Sokolenko, Sofia V, Baskina, Aigul R, Venina, Elena I, Anisimova, Ilya V, Bizin, Alexandr O, Ivantsov, Yana V, Belysheva, Alexandra P, Chernyakova, Alexandr V, Togo, Evgeny N, Imyanitov
Publikováno v:
Breast cancer research and treatment. 192(2)
Germline mutations in CHEK2 gene represent the second most frequent cause of hereditary breast cancer (BC) after BRCA1/2 lesions. This study aimed to identify the molecular characteristics of CHEK2-driven BCs.Loss of heterozygosity (LOH) for the rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3699d4a9b75bc9bbbde306245b181aa8
https://pubmed.ncbi.nlm.nih.gov/35020107
https://pubmed.ncbi.nlm.nih.gov/35020107